Skip to main content

Table 4 The significant SNP associations with breast cancer considering allelic and Cochran-Armitage trend tests

From: Common low-penetrance risk variants associated with breast cancer in Polish women

dbSNP IDa Region Geneb MA G1 vs G2 OR (95% CI) Allelic Cochran-Armitage
p-value p-valuecor p-value p-valuecor
rs10941679 5p12   0.24 C vs N 1.14 (1.01-1.28) 2.97E-02 4.75E-01 2.71E-02 4.34E-01
     C noMut vs N 1.15 (1.02-1.30) 2.29E-02 3.66E-01 2.04E-02 3.27E-01
     S vs N 1.17 (1.01-1.35) 4.25E-02 6.80E-01 3.94E-02 6.31E-01
     S noMut vs N 1.20 (1.03-1.40) 2.06E-02 3.29E-01 1.87E-02 2.99E-01
rs2736098 5p15.33 TERT 0.36 C vs N 0.77 (0.68-0.88) 5.81E-05 9.30E-04 5.51E-05 8.82E-04
     C noMut vs N 0.78 (0.69-0.89) 2.37E-04 3.78E-03 2.25E-04 3.60E-03
     C with Mut vs N 0.74 (0.57-0.94) 1.70E-02 2.73E-01 1.55E-02 2.48E-01
     F vs N 0.81 (0.69-0.93) 4.68E-03 7.49E-02 4.56E-03 7.30E-02
     F noMut vs N 0.80 (0.68-0.94) 8.63E-03 1.38E-01 8.25E-03 1.32E-01
     S vs N 0.74 (0.63-0.87) 2.61E-04 4.17E-03 2.38E-04 3.80E-03
     S noMut vs N 0.76 (0.64-0.90) 1.46E-03 2.34E-02 1.36E-03 2.18E-02
rs13281615 8q24.21   0.45 C vs N 1.19 (1.07-1.32) 1.23E-03 1.97E-02 1.17E-03 1.88E-02
     C noMut vs N 1.21 (1.08-1.35) 7.23E-04 1.16E-02 6.77E-04 1.08E-02
     F vs N 1.20 (1.06-1.35) 5.19E-03 8.31E-02 5.24E-03 8.39E-02
     F noMut vs N 1.22 (1.06-1.39) 4.60E-03 7.36E-02 4.53E-03 7.25E-02
     S vs N 1.18 (1.03-1.35) 1.61E-02 2.57E-01 1.42E-02 2.27E-01
     S noMut vs N 1.20 (1.04-1.38) 1.09E-02 1.74E-01 9.61E-03 1.54E-01
rs1219648 10q26 FGFR2 0.41 C vs N 1.30 (1.17-1.45) 1.01E-06 1.62E-05 1.13E-06 1.81E-05
     C noMut vs N 1.36 (1.22-1.52) 7.20E-08 1.15E-06 7.95E-08 1.27E-06
     F vs N 1.26 (1.11-1.43) 4.21E-04 6.73E-03 3.76E-04 6.01E-03
     F noMut vs N 1.33 (1.16-1.53) 4.02E-05 6.43E-04 3.24E-05 5.18E-04
     S vs N 1.36 (1.19-1.56) 7.32E-06 1.17E-04 8.53E-06 1.36E-04
     S noMut vs N 1.39 (1.20-1.59) 5.58E-06 8.92E-05 6.76E-06 1.08E-04
rs2981582 10q26 FGFR2 0.41 C vs N 1.31 (1.17-1.45) 9.10E-07 1.46E-05 1.17E-06 1.88E-05
     C noMut vs N 1.35 (1.21-1.51) 1.20E-07 1.91E-06 1.54E-07 2.46E-06
     F vs N 1.26 (1.11-1.43) 4.05E-04 6.48E-03 4.09E-04 6.54E-03
     F noMut vs N 1.32 (1.15-1.51) 6.49E-05 1.04E-03 6.11E-05 9.77E-04
     S vs N 1.37 (1.19-1.56) 5.70E-06 9.12E-05 7.67E-06 1.23E-04
     S noMut vs N 1.38 (1.20-1.59) 5.69E-06 9.11E-05 7.97E-06 1.27E-04
rs3817198 11p15.5 LSP1 0.34 F vs N 1.16 (1.02-1.32) 2.45E-02 3.92E-01 2.36E-02 3.78E-01
     F noMut vs N 1.16 (1.00-1.33) 4.46E-02 7.14E-01 4.34E-02 6.94E-01
rs3803662 16q12.1 TOX3 0.30 C vs N 1.13 (1.01-1.27) 3.14E-02 5.02E-01 3.22E-02 5.15E-01
     C noMut vs N 1.16 (1.03-1.31) 1.30E-02 2.08E-01 1.35E-02 2.16E-01
     F noMut vs N 1.16 (1.00-1.34) 4.45E-02 7.11E-01 4.53E-02 7.25E-01
     S noMut vs N 1.16 (1.00-1.35) 4.75E-02 7.61E-01 4.82E-02 7.71E-01
  1. Bold denotes significant association after multiple testing adjustment (p-value cor < 0.05). G1 vs. G2; compared groups of cases and controls, respectively, MA; minor allele (+) strand frequency, OR; odds ratio, CI; confidence interval, N; control, C; cancer (all cases), F; familial cancer, S; sporadic cancer, noMut; non-mutation carriers.
  2. a/SNP identifier based on NCBI SNP database;
  3. b/NCBI ID of genes localized in proximity to the SNPs of interest (source: HapMap).